Found: 25
Select item for more details and to access through your institution.
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00934-x
- By:
- Publication type:
- Article
Against the self: dendritic cells versus cancer.
- Published in:
- APMIS, 2003, v. 111, n. 7/8, p. 805, doi. 10.1034/j.1600-0463.2003.11107812.x
- By:
- Publication type:
- Article
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism.
- Published in:
- Nature Biotechnology, 2000, v. 18, n. 5, p. 509, doi. 10.1038/75365
- By:
- Publication type:
- Article
Trial designs and endpoints for immune therapies in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, p. S35, doi. 10.1002/ajh.26753
- By:
- Publication type:
- Article
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02616
- By:
- Publication type:
- Article
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.
- Published in:
- NPJ Genomic Medicine, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41525-022-00340-x
- By:
- Publication type:
- Article
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620720987075
- By:
- Publication type:
- Article
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 1, p. 32, doi. 10.1016/j.clml.2023.09.004
- By:
- Publication type:
- Article
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 11, p. 853, doi. 10.1016/j.clml.2022.07.001
- By:
- Publication type:
- Article
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 192, doi. 10.1016/j.clml.2021.09.015
- By:
- Publication type:
- Article
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 2, p. 129, doi. 10.1016/j.clml.2021.09.004
- By:
- Publication type:
- Article
P-071: Multi-omic analysis of the tumor microenvironment reveals novel associations in a clinical trial of atezolizumab ± daratumumab for relapsed/refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S78, doi. 10.1016/S2152-2650(21)02205-9
- By:
- Publication type:
- Article
P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. e470, doi. 10.1016/j.clml.2020.12.026
- By:
- Publication type:
- Article
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Neoantigen-specific CD4+ T cells induce protective, tumor-specific CD8+ T cells in a mouse model of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e157, doi. 10.1016/j.clml.2019.09.261
- By:
- Publication type:
- Article
MAGE-A3 mediates survival and proliferation through regulation of BIM and p21Cip1 in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e127, doi. 10.1016/j.clml.2019.09.210
- By:
- Publication type:
- Article
High dimensional profiling of the immune microenvironment in smoldering multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e27, doi. 10.1016/j.clml.2019.09.041
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 6, p. 616, doi. 10.1002/ajh.23705
- By:
- Publication type:
- Article
The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 11, p. 870
- By:
- Publication type:
- Article
Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma.
- Published in:
- 2023
- By:
- Publication type:
- Case Study